Downregulation of Na⁺/Ca²⁺ Exchanger Isoform 1 Protects Isolated Hearts by Sevoflurane Postconditioning but Not by Delayed Remote Ischemic Preconditioning in Rats

Yang Yu, Cheng-Hui Zhou, Yun-Tai Yao, Li-Huan Li
Department of Anesthesiology, Fuwai Cardiovascular Hospital, Beijing 100037, China

Background: Calcium regulatory proteins—L-type Ca²⁺ channels (LTCCs), ryanodine receptor 2 (RyR2), and Na⁺/Ca²⁺ exchanger isoform 1 (NCX1) have been recognized as important protective mechanisms during myocardial ischemia-reperfusion injury (I/RI). Both sevoflurane postconditioning (SevoPoC) and delayed remote ischemic preconditioning (DRIPC) have been shown to protect the heart against I/RI. In this study, we aimed to compare the effects of SevoPoC and DRIPC on the expression of the three calcium regulatory proteins in an isolated rat heart model.

Methods: After 30-min balanced perfusion, isolated hearts from rats were subjected to 30-min ischemia followed by 60-min reperfusion. Totally 40 isolated hearts were randomly assigned to four groups (n = 10/group): time control group, I/RI group, SevoPoC group, and DRIPC group. The effect of SevoPoC (3% v/v) and DRIPC were observed. Myocardial infarct size (IS), cardiac troponin I level, and heart function were measured. The protein and messenger RNA levels of LTCCs, RyR2, and NCX1 were determined.

Results: Both SevoPoC and DRIPC improved the recovery of myocardial function, and reduced cardiac troponin I release after I/RI. The decrease in IS was more significant in the SevoPoC group than that in the DRIPC group (16.50% ± 4.54% in the SevoPoC group [P = 0.0006], and 22.34% ± 4.02% in the DRIPC group [P = 0.0007] vs. 35.00% ± 5.24% in the I/RI group, respectively). SevoPoC, but not DRIPC significantly inhibited the activity of NCX1 (0.32 ± 0.16 in the SevoPoC group, P = 0.006; vs. 0.57 ± 0.14 in the DRIPC group, P = 0.072). No statistical significant differences were observed in the expression of LTCCs and RyR2 between SevoPoC and DRIPC. In addition, subsequent correlation analysis showed a significantly positive relationship between the cardiac troponin I level and the protein expression of NCX1 (r = 0.505, P = 0.023).

Conclusion: SevoPoC may be more effective in the cardioprotection than DRIPC partly due to the deactivation of NCX1.

Key words: Calcium Regulatory Protein; Delayed Remote Ischemic Preconditioning; Ischemia-reperfusion Injury; Na⁺/Ca²⁺ Exchanger; Sevoflurane Postconditioning

INTRODUCTION
Coronary heart disease, which manifests as myocardial ischemia-reperfusion injury (I/RI), is now the leading cause of death worldwide. The noninvasive protective interventions, including sevoflurane postconditioning (SevoPoC) and remote ischemic preconditioning (RIPC) remain the promising approaches which harness the body’s endogenous protective capabilities against the injury elicited by ischemia and reperfusion. Sevoflurane, a commonly used volatile anesthetic, has been demonstrated to protect the heart at the onset of reperfusion in clinical and experimental studies.[1,2] Similar cardiac effect has also been shown in RIPC by applying the protective stimulus at one tissue or organ remote from the heart before a sustained myocardial ischemia.[1,3] Two

Address for correspondence: Prof. Li-Huan Li, Department of Anesthesiology, Fuwai Cardiovascular Hospital, Beijing 100037, China
E-Mail: lilihuan_fuwai@163.com

The content of this paper has been presented at the 95th Annual Meeting of American Association for Thoracic Surgery as an abstract style.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com
© 2017 Chinese Medical Journal | Produced by Wolters Kluwer - Medknow

Received: 26-04-2017 Edited by: Yuan-Yuan Ji
How to cite this article: Yu Y, Zhou CH, Yao YT, Li LH. Downregulation of Na⁺/Ca²⁺ Exchanger Isoform 1 Protects Isolated Hearts by Sevoflurane Postconditioning but Not by Delayed Remote Ischemic Preconditioning in Rats. Chin Med J 2017;130:2226-33.
different phases of protection exerted by RIPC have been proposed: early phase (<4 h) and delayed phase (24–72 h). It has also been successfully applied for cardioprotection in coronary artery bypass grafting and percutaneous coronary intervention (PCI) procedures.

Numerous studies have concerned about the mechanisms of these two noninvasive approaches. Currently, it is believed that both SevoPoC and early RIPC could activate reperfusion injury salvage kinase (RISK) pathway, comprising phosphoinositide 3-kinase-protein kinase B/Akt and extracellular signal-regulated kinase 1 and 2, and Survivor Activating Factor Enhancement (SAFE) such as STAT3. However, there is little information on the mechanisms responsible for the cardioprotection by delayed remote ischemic preconditioning (DRIPC). Our previous findings in animal hearts have found that DRIPC could activate nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) and Heme oxygenase-1, but not the RISK pathway in SevoPoC. As known to all, SevoPoC (after ischemia) and delayed RIPC (before ischemia) could exert similar cardioprotection in different periods. Hence, novel differential underlying mechanisms still need to be further elucidated.

Calcium regulatory proteins are mainly composed of L-type Ca$^{2+}$ channels (LTCCs), ryanodine receptor 2 (RyR2), and Na$^+$/Ca$^{2+}$ exchanger (NCX). These proteins have been proposed as important mechanisms responsible for myocardial I/RI in recent years. However, there have been few studies investigating the effects of SevoPoC and DRIPC on the expression of calcium regulatory proteins. Therefore, we compared the expression of LTCCs, RyR2, and NCX1 between SevoPoC and DRIPC in a Langendorff perfused rat heart model and tried to explore the potential role in cardioprotection.

**Methods**

**Animals**

All experimental procedures were reviewed and approved by the Animal Care and Use Committee of Fuwai Cardiovascular Hospital, and all animals received appropriate care according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (revised in 1996). The researchers who performed the animal experiments, possessed qualified certifications issued by Beijing Association on Laboratory Animal Care (Beijing, China). Adult, male Sprague-Dawley (SD) rats (250–300 g) obtained from Vital River Experimental Animal Company (Beijing, China), were kept in a controlled environment with access to food and water.

**Langendorff heart preparation, and hemodynamics monitoring**

SD rats were heparinized (1000 IU/kg) and anesthetized by intraperitoneal injection of ethyl carbamate. Each rat received the tail-clamp test to make sure that it was pain-free before the operation. After 2% lidocaine was infiltrated into the incision, the hearts were rapidly excised and placed into ice-cold phosphate buffer solution, mounted on a modified noncircularizing Langendorff apparatus. Then, hearts were perfused with 95% oxygen oxygenated Krebs-Henseleit (K-H) buffer solution containing (in mmol/L): NaCl 118.5, KCl 4.75, MgSO$_4$ 1.19, NaHCO$_3$ 25.0, KH$_2$PO$_4$ 1.2, glucose 11.0, HEPES 10.0, and CaCl$_2$ 1.4, at a constant flow rate of 10 ml/min. A small saline-filled latex balloon connected with a pressure transducer was inserted through the left atrium and pushed through the mitral valve into the left ventricle. The balloon volume was adjusted to achieve an end-diastolic pressure of 0-10 mmHg. The cardiac function was then recorded through LabChart 7.0 (AD Instruments Inc., Colorado Springs, CO, USA). Characteristic data derived from left ventricular pressure measurement were used to determine the developed pressure (LVDP), left ventricular end-diastolic pressure (LVEDP), and maximum LVDP increase (±dp/dt), and decrease (−dp/dt) rate as indices of contractility and relaxation, and heart rate (HR).

**Experimental protocols**

After a stabilization period of 30 min, 40 isolated hearts were randomly assigned to four groups ($n = 10$ /group; Figure 1): (1) time control group: continuous perfusion for 120 min; (2) I/RI group: ischemia for 30 min followed by 60-min reperfusion; (3) SevoPoC group: perfused with 3% (v/v) sevoflurane-bubbled KHBS (Maruishi Pharmaceutical Co., Japan) oxygenated with 95% oxygen for 10 min at the onset of reperfusion and then with normal KHBS for the remaining 50 min. The concentration was monitored by an anesthetic gas monitor (Datex Capnomac Ultima, Division of Instrumentarium Corp., Helsinki, Finland) and a gas chromatograph (GC/MSQP2010PLUS, Shimadzu, Kyoto, Japan): 3% (v/v) sevoflurane (0.51 ± 0.04 mmol/L); (4) DRIPC group: 4 cycles of 5-min occlusion and 5-min reflow at unilateral hind limb once at the day before heart isolation. Ischemia was confirmed using modified pulse oxymetry for the rats with anesthesia by ethyl carbamate (intraperitoneally, 1.0 g/kg).

**Cardiac troponin I detection**

Coronary effluent (1 ml) was collected at the baseline and at the end of 60-min perfusion for the detection of cardiac troponin I (cTnI) levels using ACS: 180 automated chemiluminescence system with commercial kits (Bayer Corp., Tarrytown, NY, USA). All coronary effluent samples were coded, and the laboratory investigator was blinded to the treatment regimen.

**Infarct size determination**

Myocardial infarct size (IS) was determined using 2,3,5-triphenyltetrazolium chloride (TTC; Sigma-Aldrich, St. Louis, MO, USA) staining ($n = 5$). At the end of reperfusion, hearts were frozen at −20°C for 1 h, and subsequently sliced into 5 sections of equal thickness (≈1 mm). The slices were incubated in 0.1% TTC solution for 10 min at 37°C and stained.
Tukey test for multiple comparisons was performed to validate the specific generation of the expected PCR product. The expression of each gene was normalized as ΔΔCt (ΔCt of target gene – Ct of internal control gene) using 18SrRNA as the control. Relative quantification using the ΔΔCt method was applied to compare the amounts of mRNA.

There were 10 isolated rat hearts in each group after the Langendorff protocols. Five of the 10 hearts were sliced to determine the IS, and the remaining 5 ventricular tissue samples were collected to detect the protein and mRNA levels of the three calcium regulatory proteins. We used the correlation analysis to detect the relationship between the cardiac troponin I level and the protein expression of NCX1.

**Statistical analysis**

The sample size was chosen according to the previous studies by our group.\(^{10,12}\) Data were expressed as mean ± standard deviation (SD). The variables of LV contractile function were analyzed using two-way analysis of variance (ANOVA). For all other data, one-way ANOVA with post hoc Tukey test for multiple comparisons was used. All statistical analyses were performed in SPSS version 13.0 (IBM, Armonk, New York, USA). \(P < 0.05\) was considered statistically significant.

**Results**

**Effects on hemodynamic parameters**

As shown in Table 1, no significant differences were observed in baseline hemodynamic parameters among all experimental groups \((P = 0.068)\). During the reperfusion, a dramatically elevated LVEDP and significant decreases in RPP (the product of HR and LVDP) and ±dp/dt were observed in the I/RI group \((P = 0.036)\). Compared with the SevoPoC group, the significant decreases in RPP were observed in the DRIPC group \((P = 0.027; \text{Table 1})\).

---

**Western blotting**

The left ventricular tissue samples were collected, immediately snap frozen in liquid nitrogen, and stored at \(-80^\circ\text{C}\) for further analyses. Samples were then powdered under liquid nitrogen and homogenized in lysis buffer (20 mmol/L Tris- HCl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L ethylenediamine tetra-acetate, 1 mmol/L EGTA, 1% Triton, 3% sodium dodecyl sulfate [SDS], 1 mmol/L phenylmethylsulfonyl fluoride, and 5 mg/ml protease inhibitor cocktail). The homogenates were vortexed for 15 s and then centrifuged at 14,000 \(\times g\) for 10 min at \(4^\circ\text{C}\). Protein concentrations were determined by the Bradford method using bovine serum albumin as a standard. Equal amounts of protein were electrophoresed on a 12.5% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane, and probed with polyclonal primary antibodies specific for total LTCCs, the RyR2, and the NCX. Coomasie blue and Ponceau red were used to verify adequate transfer of proteins from the gel to the membrane. \(\beta\)-actin was used to ensure equal protein loading. The membranes were washed and incubated with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (Santa Cruz Biotechnology Inc., CA, USA). Proteins were detected using chemiluminescence; bands were visualized by exposure to photographic film (Fuji Protein, Tokyo, Japan). Quantitative analysis of the band densities was performed using Image 1.63 software (National Institute of Health, Bethesda, Maryland, USA).

**Real-time polymerase chain reaction**

The messenger RNA (mRNA) level of LTCCs, RyR2, NCX1 were analyzed by real-time polymerase chain reaction (PCR). Total RNA was isolated from the LV samples lysed in Trizol solution (Invitrogen, Carlsbad, CA, USA). The RNA samples were then reversely transcribed to the first strand complementary DNA (cDNA) synthesis kit (Roche, Indianapolis, IN, USA) in a 20 ml reaction system. The cDNA was then amplified with Universal SYBR kit (Roche, Indianapolis, IN, USA) using the following primers (20 mmol/L Tris- HCl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L ethylenediamine tetra-acetate, 1 mmol/L EGTA, 1% Triton, 3% sodium dodecyl sulfate [SDS], 1 mmol/L phenylmethylsulfonyl fluoride, and 5 mg/ml protease inhibitor cocktail). The homogenates were vortexed for 15 s and then centrifuged at 14,000 \(\times g\) for 10 min at \(4^\circ\text{C}\). Protein concentrations were determined by the Bradford method using bovine serum albumin as a standard. Equal amounts of protein were electrophoresed on a 12.5% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane, and probed with polyclonal primary antibodies specific for total LTCCs, the RyR2, and the NCX. Coomasie blue and Ponceau red were used to verify adequate transfer of proteins from the gel to the membrane. \(\beta\)-actin was used to ensure equal protein loading. The membranes were washed and incubated with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (Santa Cruz Biotechnology Inc., CA, USA). Proteins were detected using chemiluminescence; bands were visualized by exposure to photographic film (Fuji Protein, Tokyo, Japan). Quantitative analysis of the band densities was performed using Image 1.63 software (National Institute of Health, Bethesda, Maryland, USA).

**Results**

**Effects on hemodynamic parameters**

As shown in Table 1, no significant differences were observed in baseline hemodynamic parameters among all experimental groups \((P = 0.068)\). During the reperfusion, a dramatically elevated LVEDP and significant decreases in RPP (the product of HR and LVDP) and ±dp/dt were observed in the I/RI group \((P = 0.036)\). Compared with the SevoPoC group, the significant decreases in RPP were observed in the DRIPC group \((P = 0.027; \text{Table 1})\).

---

**Figure 1:** Experimental protocol. Hearts were randomly assigned in one of the above experimental groups \((n = 10)\). TC: Time control; I/RI: Ischemia/reperfusion injury; SevoPoC: Sevoflurane postconditioning; DRIPC: Delayed remote ischemic preconditioning; Sevo: Sevoflurane.
**Table 1: Hemodynamic parameters in all rat groups**

| Items               | TC group          | I/RI group       | SevoPoC group      | DRIPC group       |
|---------------------|-------------------|------------------|--------------------|------------------|
| LVEDP (mmHg)        |                   |                  |                    |                  |
| Baseline            | 6.8 ± 2.7         | 4.7 ± 1.9        | 5.3 ± 2.5          | 5.0 ± 3.1        |
| Reperfusion         |                   |                  |                    |                  |
| 30 min              | 4.3 ± 1.5         | 31.6 ± 14.4*     | 19.9 ± 5.7*†       | 24.9 ± 8.9*†     |
| 60 min              | 4.7 ± 1.2         | 34.4 ± 14.3*†    | 21.3 ± 7.1*†       | 23.3 ± 7.8*†     |
| Recovery of RPP (mmHg) |                |                  |                    |                  |
| Baseline            | 52977.6 ± 3242.8  | 58567.6 ± 3170.9 | 53724.0 ± 3649.4   | 56054.8 ± 3130.8 |
| Reperfusion         | 55997.3 ± 2648.9  | 43984.3 ± 3221.2*† | 51682.5 ± 3545.8*† | 48365.7 ± 2797.7*† |
| 60 min              | 54090.1 ± 3019.7  | 44277.1 ± 3514.1*† | 52327.2 ± 3814.4†  | 51642.0 ± 1235.8*† |
| Recovery of +dp/dt (mmHg) |          |                  |                    |                  |
| Baseline            | 5033.5 ± 564.8    | 4841.0 ± 448.4   | 5286.4 ± 960.5     | 4643.1 ± 367.8   |
| Reperfusion         | 5491.5 ± 755.0    | 3955.1 ± 493.8*† | 5053.8 ± 655.5†    | 4285.5 ± 466.2*† |
| 60 min              | 5728.1 ± 664.4    | 3795.3 ± 522.8*† | 4842.4 ± 798.3†    | 4450.5 ± 457.6*† |
| Recovery of −dp/dt (mmHg) |          |                  |                    |                  |
| Baseline            | 3340.8 ± 322.6    | 3040.9 ± 380.6   | 3186.7 ± 343.7     | 2814.3 ± 222.8   |
| Reperfusion         | 3544.6 ± 273.9    | 2317.2 ± 243.3*† | 3008.2 ± 328.2†    | 2630.1 ± 346.1*† |
| 60 min              | 3484.4 ± 297.3    | 2359.8 ± 279.8*† | 2984.4 ± 417.0*†   | 2831.9 ± 312.4*† |

Data are presented as mean ± SD (n=10). *P<0.05 versus baseline; †P<0.05 versus TC group; ‡P<0.05 versus I/RI group; §P<0.05 versus SevoPoC group. TC: Time control; I/RI: Ischemia/reperfusion injury; SevoPoC: Sevoflurane postconditioning; DRIPC: Delayed remote ischemic preconditioning; LVEDP: Left ventricular end-diastolic pressure; RPP: The product of HR and LVDP; LVDP: Left ventricular developed pressure; ±dp/dt: Maximum LVDP increase (+dp/dt) and decrease (−dp/dt) rate; HR: Heart rate; SD: Standard deviation.

**Infarct size and cardiac enzyme release**

SevoPoC or DRIPC reduced the IS caused by I/RI (16.50% ± 4.54% in the SevoPoC group [P = 0.0006] and 22.34% ± 4.02% in the DRIPC group [P = 0.0007], vs. 35.00% ± 5.24% in the I/RI group, respectively; Figure 2a and 2b). As a specific marker of myocardial injury, the baseline values of cTnI in all groups were not significantly different. The cTnI levels at the end of reperfusion were largely increased in the I/RI group, whereas less releas was observed both in the SevoPoC group (P = 0.0005) and in the DRIPC group (P = 0.0005; Figure 2c).

**Expression of L-type Ca²⁺ channels, ryanodine receptor 2 and Na⁺/Ca²⁺ exchanger isofrom 1**

Western blotting study showed that NCX1 expression was significantly decreased in the SevoPoC group (0.32 ± 0.16 vs. 0.59 ± 0.09 in the I/RI group, P = 0.006) but not in the DRIPC group [0.57 ± 0.14 vs. 0.59 ± 0.09 in the I/RI group, P = 0.072; Figure 3a and 3b]. No statistical differences were observed in the expression of LTCCs and RyR2 [Figure 3c and 3d]. Despite the transcriptional level of RyR2 in SevoPoC group seemed to be substantially reduced, there was no statistical difference [P = 0.065; Figure 4b]. The difference of mRNA regulation among LTCCs, NCX1 was not observed in both SevoPoC and DRIPC group [P = 0.081; Figure 4a and 4c]. Moreover, the cardiac troponin I level was significantly positively correlated with the protein expression of NCX1 [Pearson correlation: r = 0.505, P = 0.023; Figure 4d].

**Discussion**

In the current study, we found that SevoPoC and DRIPC offer similar cardioprotection by improving the recovery of myocardial function, reducing cTnI release, and decreasing IS after I/RI. However, SevoPoC may provide more ability to regulate calcium regulatory proteins than DRIPC, especially in the deactivation of NCX1.

It has always been a research focus for comparing the adaptive cardioprotective procedures and relevant mechanisms in different phases. Halkos et al.[19] compared ischemic preconditioning (IPC) and ischemic postconditioning (IPoC), finding that in comparison with IPC, IPoC can only reduce ROS generation during early reperfusion by mechanisms other than those engaged by preconditioning, and explored the mechanism in terms of lipid peroxidation and ROS generation. Deyhimy et al.[20] found that sevoflurane preconditioning (SevoPC) and SevoPoC, were shown to be equally effective in protecting myocardial function, and investigated the mechanisms in terms of intracellular concentrations of Na⁺, H⁺ and Ca²⁺. Both Xin et al.[21] and Tamareille et al.[22] found that remote ischemic preconditioning was as efficacious as local IPC in protecting myocardium from myocardial I/RI, and explored the involvement of RISK and SAFE signal pathways. Moreover, other researches focused on SevoPC and ischemic late preconditioning,[23] early and late ischemic preconditioning,[24] and SevoPC and SevoPoC,[25] all of which highlighted the importance of adenosine triphosphate-regulated potassium (KATP) channels and mitochondria. Our groups have previously compared the two noninvasive protective approaches, for
DRIPC could confer cardioprotection from myocardial I/R injury, as manifested by significantly improved cardiac function, reduced cTnI release, and in particular the decreased IS. In addition, there were marked differences in the calcium regulatory protein expression between SevoPoC and DRIPC.

Calcium regulatory protein plays a crucial role in maintaining Ca\(^{2+}\) homeostasis in the heart under the physiologic condition, and abnormal Ca\(^{2+}\) handling has been considered to be a major downstream effect that ultimately promotes the cardiomyocyte damage. The expression of NCX1 has been known to increase both at mRNA and protein level in failing heart due to ischemic cardiomyopathy.\[17\] Accumulating evidence indicates that NCX1-mediated Ca\(^{2+}\) overload contributes to the death of cardiomyocytes during IR-injury, the inhibition of NCX exerted a protective effect in ischemic ventricular myocytes making NCX1 as an effective therapeutic target for preventing IR-induced cardiomyocyte death.\[18,25,26\] However, evidence indicates that cellular mechanisms involved could be different in LTCCs and RyR2 activities,\[19,20\] in our study, we found that only NCX1 was of significant importance in the cardioprotective effect, especially elicited by SPoC. Based on these evidence, the activation of calcium regulatory protein during cardiac IR injury prevention may be with the discrepancy, partly due to the types of IR model, animal species, and conditioning protocols and timing.

Several relevant publications have concerned about the effect of conditioning strategies on the calcium regulatory proteins. Ma et al.\[27\] using neonatal rat heart model found that the cardioprotection by preconditioning with chronic intermittent hypoxia (CIH) was mediated by preserving NCX1 expression. In addition to NCX1 expression, two studies also established the augmentation of RYRs activity in CIH-induced cardioprotection in adult rat heart models.\[24,28\] Contrary finding from Collins et al.\[29\] revealed that preconditioning-like effect by daily exercise could alter calcium regulatory proteins by decreasing NCX expression in hypertensive rat hearts, indicating that the mechanisms underlying the calcium regulatory protein expression may be conditioning-specific. In this study, the effects of SevoPoC and DRIPC on the three regulatory proteins were systematically investigated both in translational and transcriptional levels. Furthermore, in support of the proposed indication, we did find a differential regulation of NCX1 between SevoPoC and DRIPC.

Although the present data are unable to tell the exact molecular mechanisms underlying the differential expression of NCX1 between SevoPoC and DRIPC, we believe that there are several putative involving signal pathways according to the current publications. First, a previous study using an adult cardiomyocyte model has demonstrated that the inhibition of Ca\(^{2+}\)/calmodulin-dependent protein kinase II (CaMKII) activity could prevent NCX1 upregulation.\[30\] Akiko et al. demonstrated that sevoflurane exerted the cardioprotection against I/R injury through an inhibitory action on CaMKII activity.\[31\] On the other hand, β-adrenergic pathway has been widely proposed as an important mechanistic...
The potential involvement of β-adrenergic pathway in anesthetic-pretreatment cardioprotection, including SevoPoC and desflurane postconditioning. The β-adrenergic receptors transduced signals to the second messenger cyclic adenosine monophosphate which has been reported to inhibit NCX. However, there were few relevant publications upon the CaMKII nor β-adrenergic pathway in DRIPC. In the present study, SevoPoC was shown to provide cardioprotection by deactivating NCX1. This mechanism was supported by the correlation analysis revealing a positive relationship between the cardiac troponin I level and the protein expression of NCX1. However, this association should be verified through investigating the influence of ion channels using specific inhibitors in the future. Taken together, these indications may explain the differential regulation in NCX1 between SevoPoC and DRIPC group. The mRNA level was similar between SevoPoC and DRIPC group indicating an involvement of nontranscriptional differential regulation. Hence, the detailed mechanisms should be verified in future studies.

There are several limitations in the current study. First, we evaluated the process of I/RI in the Langendorff model, in which the hearts were denervated and could not reflect the potential role of neurohumor factors. Second, most studies, including ours, investigated the mechanism of I/RI using juvenile and healthy hearts, which is different from clinical setting where patients with various co-morbidities (such as gender and age) and/or co-medications (β-blockers), however, accumulating evidence has shown that unhealthy myocardium may be less amenable to protective interventions. Third, we investigated the influence of ion channels without using specific inhibitor, such as KB-R7943 (the inhibitor of NCX). Fourth, we did not observe the cytosolic Ca²⁺ concentrations, especially the intracellular diastolic Ca²⁺ concentrations, which may be a direct parameter of the activation of the NCX and contribute to the explanations of the underlying mechanism of I/RI. Finally, the data presented in this paper while suggestive, are insufficient to make a definitive conclusion. Further studies are needed to elucidate the underlying pathways and their detailed interaction and discrepancy.

In conclusion, using a Langendorff perfused rat heart model, the findings from this study suggest that SevoPoC may be more effective in the cardioprotection than DRIPC partly due to the deactivation of NCX1.
Financial support and sponsorship
This work was supported by grants from the National Natural Scientific Foundation of China (No. 81400271 and No. 81200109) and Doctoral Program of Higher Education of China (No. 20121106120008).

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Yao YT, Fang NX, Shi CX, Li LH. Sevoflurane postconditioning protects isolated rat hearts against ischemia-reperfusion injury. Chin Med J 2010;123:1320-8. doi: 10.3760/cma.j.isn.0366-6999.2010.10.018.

2. Zaugg M, Lucchinetti E. Sevoflurane – Compared with propofol-based anesthesia reduces the need for inotropic support in patients undergoing abdominal aortic aneurysm repair: Evidence of cardioprotection by volatile anesthetics in noncardiac surgery. Anesthesiology 2014;120:1289-90. doi: 10.1097/ALN.0000000000000186.

3. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893-9. doi: 10.1161/01.CIR.87.3.893.

4. Kanoria S, Jalan R, Seilfian AM, Williams R, Davidson BR. Protocols and mechanisms for remote ischemic preconditioning: A novel method for reducing ischemia reperfusion injury. Transplantation 2007;84:445-58. doi: 10.1097/01.tp.0000228323.55419.e8.

5. Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: A randomised controlled trial. Lancet 2007;370:575-9. doi: 10.1016/S0140-6736(07)61296-3.

6. Ali ZA, Callaghan C, Lim E, Ali AA, Nourae SA, Akhtar AM, et al. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: A randomized controlled trial. Circulation 2007;116:998-105. doi: 10.1161/circulationaha.107.166682.

7. Obal D, Dettwiler S, Favoccia C, Scharbatke H, Preckel B, Schlack W, et al. The influence of mitochondrial KATP-channels in the cardioprotection of preconditioning and postconditioning by sevoflurane in the rat in vivo. Anesth Analg 2005;101:1252-60. doi: 10.1213/01.ANE.0000181336.96511.32.

8. Sun J, Tong L, Luan Q, Deng J, Li Y, Li Z, et al. Protective effect of delayed remote limb ischemic preconditioning: Role of mitochondrial K(A TP) channels in a rat model of focal cerebral ischemic reperfusion injury. J Cereb Blood Flow Metab 2012;32:851-9. doi: 10.1038/jcbfm.2011.199.

9. Waldron S, Schneider K, Heidbreder M, Nienstedt J, Dominiak P, Dendorfer A, et al. Remote preconditioning protects the heart by activating myocardial PKCepsilon-isoform. Cardiovasc Res 2002;55:583-9. doi: 10.1016/S0008-6363(02)00408-X.

10. Chen D, Cheng B, Zhou HY, Li LH. The effect of sevoflurane postconditioning on cardioprotection against ischemia-reperfusion injury in rabbits. Mol Biol Rep 2012;39:609-17. doi: 10.1007/s11033-011-1419-5.

11. Chen HT, Yang CX, Li H, Zhang CJ, Wen XJ, Zhou J, et al. Cardioprotection of sevoflurane postconditioning by activating extracellular signal-regulated kinase 1/2 in isolated rat hearts. Acta Pharmacol Sin 2008;29:931-41. doi: 10.1111/j.1745-7254.2008.00824.x.

12. Fang NX, Yao YT, Shi CX, Li LH. Attenuation of ischemia-reperfusion injury by sevoflurane postconditioning involves protein kinase B and glycogen synthase kinase 3 beta activation in isolated rat hearts. Mol Biol Rep 2010;37:3763-9. doi: 10.1007/s11033-010-0030-5.

13. Breivik L, Helgeland E, Aarnes EK, Mrdalj J, Jonassen AK. Remote
postconditioning by humoral factors in ischemic preconditioned rat hearts is mediated via PKD/Akt-dependent cell-survival signaling at reperfusion. Basic Res Cardiol 2011;106:135-45. doi: 10.1007/s00395-010-0133-0.

14. Dow J, Bhandari A, Simkhovich BZ, Hale SL, Kloner RA. The effect of acute versus delayed remote ischemic preconditioning on reperfusion induced ventricular arrhythmias. J Cardiovasc Electrophysiol 2012;23:1374-83. doi: 10.1111/j.1540-8167.2012.02397.x.

15. Zhou C, Li L, Li H, Gong J, Fang N. Delayed remote preconditioning induces cardioprotection: Role of heme oxygenase-1. J Surg Res 2014;191:51-7. doi: 10.1016/j.jss.2014.03.054.

16. Zhou C, Li H, Yao Y, Li L. Delayed remote ischemic preconditioning produces an additive cardioprotection to sevoflurane postconditioning through an enhanced heme oxygenase 1 level partly via nuclear factor erythroid 2-related factor 2 nuclear translocation. J Cardiovasc Pharmacol Ther 2014;19:558-66. doi: 10.1177/1074284914524749.

17. Fleisch M, Schwinger RH, Schiffer F, Frank K, Sidkmann M, Kuhn-Regnier E, et al. Evidence for functional relevance of an enhanced expression of the Na+/Ca2+ exchanger in failing human myocardium. Circulation 1996;94:992-1002. doi: 10.1161/01.CIR.94.5.992.

18. Piltitis JG, Diaz FG, O'Regan MH, Phillips JW. Inhibition of Na(+)/Ca2+ exchange by KB-R7943, a novel selective antagonist, attenuates phosphoethanolamine and free fatty acid efflux in rat cerebral cortex during ischemia-reperfusion injury. Brain Res 2001;916:192-8. doi: 10.1016/S0006-8993(01)02896-7.

19. Halkos ME, Kerendi F, Corvera JS, Wang NP, Kin H, Payne CS, et al. Sodium/calcium exchanger protein expression with postconditioning is not enhanced by ischemic preconditioning. Ann Thorac Surg 2004;78:961-9. doi: 10.1016/j.athoracsur.2004.03.033.

20. Deyhimy DI, Fleming NW, Brodkin IG, Liu H. Anesthetic preconditioning combined with postconditioning offers no additional benefit over preconditioning or postconditioning alone. Anesth Analg 2007;105:316-24. doi: 10.1213/01.ane.0000267254.71445.e7.

21. Xin P, Zhu W, Li J, Ma S, Wang L, Liu M, et al. Combined local ischemic preconditioning and remote postconditioning recapitulate cardioprotective effects of local ischemic preconditioning. Am J Physiol Heart Circ Physiol 2010;298:H1819-31. doi: 10.1152/ajpheart.01102.2009.

22. Tamareille S, Mateus V, Ghaboura N, Jeanneteau J, Croué A, Henrion D, et al. RISK and SAFE signaling pathway interactions in remote limb ischemic preconditioning in combination with local ischemic postconditioning. Basic Res Cardiol 2011;106:1329-39. doi: 10.1007/s00395-011-0210-z.

23. Müllenheim J, Ebel D, Bauer M, Otto F, Heinen A, Frässdorf J, et al. Sevoflurane confers additional cardioprotection after ischemic preconditioning in rabbits. Anesthesiology 2003;99:624‑31. doi: 10.1097/01.ANE.0000082842.89933.6d.

24. Müllenheim J, Schlack W, Frässdorf J, Heinen A, Preckel B, Thämer V, et al. Additive protective effects of late and early beta-adrenergic receptor stimulated ncx1. J Cardiovasc Electrophysiol 2001;1281:H2184‑90. doi: 10.1111/j.1540-8167.2001.02397.x.

25. Eigel BN, Hadley RW. Antisense inhibition of Na+/Ca2+ exchange by KB-R7943, a novel selective antagonist, attenuates phosphoethanolamine and free fatty acid efflux in rat cerebral cortex during ischemia-reperfusion injury. Brain Res 2001;916:192-8. doi: 10.1016/S0006-8993(01)02896-7.

26. Eigel BN, Hadley RW. Antisense inhibition of Na+/Ca2+ exchange by KB-R7943, a novel selective antagonist, attenuates phosphoethanolamine and free fatty acid efflux in rat cerebral cortex during ischemia-reperfusion injury. Brain Res 2001;916:192-8. doi: 10.1016/S0006-8993(01)02896-7.

27. Eigel BN, Hadley RW. Antisense inhibition of Na+/Ca2+ exchange by KB-R7943, a novel selective antagonist, attenuates phosphoethanolamine and free fatty acid efflux in rat cerebral cortex during ischemia-reperfusion injury. Brain Res 2001;916:192-8. doi: 10.1016/S0006-8993(01)02896-7.

28. Yeung HM, Kravtsov GM, Ng KM, Wong TM, Fung ML. Chronic intermittent hypoxia alters Ca2+ handling in rat cardiomyocytes by increased Na(+)/Ca2+ exchange and ryanodine receptor activities in ischemia-reperfusion. Am J Physiol Cell Physiol 2007;292:C2046-56. doi: 10.1152/ajpcell.00458.2006.

29. Collins HL, Loka AM, Dicarlo SE. Daily exercise-induced cardioprotection is associated with changes in calcium regulatory proteins in hypertensive rats. Am J Physiol Heart Circ Physiol 2005;288:H532-40. doi: 10.1152/ajpheart.00873.2004.

30. Mani SK, Egan EA, Addy BK, Grimm M, Kasigianan H, Thiyagarajan T, et al. Beta-adrenergic receptor stimulated ncx1 upregulation is mediated via a cAMKII/AP-1 signaling pathway in adult cardiomyocytes. J Mol Cell Cardiol 2010;48:342-51. doi: 10.1016/j.yjmcc.2009.11.007.

31. Kojima A, Kitagawa H, Omatsu-Kanbe M, Matsuura H, Nosaka S. Sevoflurane protects ventricular myocytes against oxidative stress-induced cellular Ca2+ overload and hypercontracture. Anesthesiology 2013;119:606-20. doi: 10.1097/ALN.0b013e318292ee52.

32. Lange M, Smul TM, Blomeyer CA, Redel A, Klotz KN, Roewer N, et al. Role of the beta1-adrenergic pathway in anesthetic and ischemic preconditioning against myocardial infarction in the rabbit heart in vivo. Anesthesiology 2006;105:503-10.

33. Lange M, Redel A, Lotz C, Smul TM, Blomeyer C, Frank A, et al. Desflurane-induced postconditioning is mediated by beta-adrenergic signaling: Role of beta 1-and beta 2-adrenergic receptors, protein kinase A, and calcium/calmodulin-dependent protein kinase II. Anesthesiology 2009;110:516-28. doi: 10.1097/ALN.0b013e318197f6e2.

34. Lange M, Redel A, Lotz C, Smul TM, Blomeyer C, Frank A, et al. Desflurane-induced postconditioning is mediated by beta-adrenergic signaling: Role of beta 1-and beta 2-adrenergic receptors, protein kinase A, and calcium/calmodulin-dependent protein kinase II. Anesthesiology 2009;110:516-28. doi: 10.1097/ALN.0b013e318197f6e2.

35. Lange M, Redel A, Lotz C, Smul TM, Blomeyer C, Frank A, et al. Desflurane-induced postconditioning is mediated by beta-adrenergic signaling: Role of beta 1-and beta 2-adrenergic receptors, protein kinase A, and calcium/calmodulin-dependent protein kinase II. Anesthesiology 2009;110:516-28. doi: 10.1097/ALN.0b013e318197f6e2.

36. Lange M, Redel A, Lotz C, Smul TM, Blomeyer C, Frank A, et al. Desflurane-induced postconditioning is mediated by beta-adrenergic signaling: Role of beta 1-and beta 2-adrenergic receptors, protein kinase A, and calcium/calmodulin-dependent protein kinase II. Anesthesiology 2009;110:516-28. doi: 10.1097/ALN.0b013e318197f6e2.